Regeneron Pharmaceuticals Q3 2024 Adj. EPS $12.46 Beats $11.69 Estimate, Sales $3.720B Beat $3.670B Estimate
Regeneron Pharmaceuticals, Inc. -0.70%
Regeneron Pharmaceuticals, Inc. REGN | 815.26 | -0.70% |
Regeneron Pharmaceuticals (NASDAQ:
REGN) reported quarterly earnings of $12.46 per share which beat the analyst consensus estimate of $11.69 by 6.59 percent. The company reported quarterly sales of $3.720 billion which beat the analyst consensus estimate of $3.670 billion by 1.36 percent. This is a 10.62 percent increase over sales of $3.363 billion the same period last year.